PHARMACIA AND UPJOHN FDA Approval NDA 021130

NDA 021130

PHARMACIA AND UPJOHN

FDA Drug Application

Application #021130

Documents

Letter2000-04-18
Letter2004-06-25
Letter2005-11-08
Letter2007-05-01
Letter2010-01-26
Letter2010-07-23
Letter2013-05-07
Letter2013-05-07
Letter2014-01-28
Label2000-04-18
Label2003-04-07
Label2003-04-07
Label2004-06-25
Label2005-05-17
Label2007-05-01
Label2008-06-26
Label2009-12-11
Label2013-05-09
Label2015-06-10
Letter2004-07-01
Letter2004-07-01
Letter2003-07-28
Letter2004-01-14
Letter2005-02-11
Letter2005-05-17
Letter2005-05-17
Letter2008-06-24
Letter2008-06-24
Letter2012-02-15
Letter2015-06-10
Label2005-05-17
Label2010-07-19
Label2013-05-09
Label2012-02-14
Label2014-01-27
Review2000-04-18
Review2005-06-27
Review2014-07-07
Letter2017-07-14
Label2017-07-14
Pediatric Medical Review1900-01-01
Pediatric Written Request1900-01-01
Pediatric Amendment 11900-01-01
Pediatric Amendment 21900-01-01
Pediatric Amendment 31900-01-01
Pediatric Amendment 41900-01-01
Pediatric Clinical Pharmacology Review1900-01-01
Label2018-02-02
Letter2018-02-02
Label2020-08-06
Label2020-08-06
Letter2020-08-06
Letter2020-08-06
Letter2021-07-19
Label2021-07-20
Letter2021-09-02
Label2021-09-13
Letter2021-10-27
Label2021-10-27

Application Sponsors

NDA 021130PHARMACIA AND UPJOHN

Marketing Status

Discontinued001
Prescription002

Application Products

001TABLET;ORAL400MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**1ZYVOXLINEZOLID
002TABLET;ORAL600MG1ZYVOXLINEZOLID

FDA Submissions

TYPE 1; Type 1 - New Molecular EntityORIG1AP2000-04-18PRIORITY
LABELING; LabelingSUPPL2AP2002-12-19STANDARD
EFFICACY; EfficacySUPPL3AP2002-12-19PRIORITY
EFFICACY; EfficacySUPPL4AP2003-07-22STANDARD
LABELING; LabelingSUPPL5AP2004-01-05STANDARD
EFFICACY; EfficacySUPPL6AP2004-06-23PRIORITY
LABELING; LabelingSUPPL7AP2005-02-10STANDARD
LABELING; LabelingSUPPL8AP2005-05-12STANDARD
EFFICACY; EfficacySUPPL9AP2005-05-12PRIORITY
LABELING; LabelingSUPPL10AP2005-11-02STANDARD
LABELING; LabelingSUPPL12AP2007-04-26STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL13AP2007-03-26PRIORITY
MANUF (CMC); Manufacturing (CMC)SUPPL14AP2007-03-21PRIORITY
MANUF (CMC); Manufacturing (CMC)SUPPL15AP2007-06-08PRIORITY
LABELING; LabelingSUPPL16AP2008-06-20STANDARD
LABELING; LabelingSUPPL17AP2008-06-20STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL18AP2007-09-18PRIORITY
MANUF (CMC); Manufacturing (CMC)SUPPL19AP2008-02-19PRIORITY
LABELING; LabelingSUPPL20AP2009-12-08STANDARD
LABELING; LabelingSUPPL22AP2010-07-16STANDARD
LABELING; LabelingSUPPL23AP2013-05-03STANDARD
LABELING; LabelingSUPPL24AP2013-05-03STANDARD
LABELING; LabelingSUPPL28AP2012-02-13STANDARD
LABELING; LabelingSUPPL32AP2014-01-24STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL33AP2014-07-28PRIORITY
LABELING; LabelingSUPPL34AP2017-07-13STANDARD
LABELING; LabelingSUPPL35AP2015-06-05STANDARD Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs.
LABELING; LabelingSUPPL37AP2018-02-01STANDARD
LABELING; LabelingSUPPL39AP2020-08-05STANDARD
LABELING; LabelingSUPPL40AP2020-08-05STANDARD
LABELING; LabelingSUPPL41AP2021-07-16STANDARD
LABELING; LabelingSUPPL42AP2021-09-01STANDARD
LABELING; LabelingSUPPL43AP2021-10-26STANDARD

Submissions Property Types

SUPPL9Null6
SUPPL13Null0
SUPPL14Null0
SUPPL15Null0
SUPPL18Null0
SUPPL19Null0
SUPPL20Null7
SUPPL22Null7
SUPPL23Null15
SUPPL24Null6
SUPPL28Null6
SUPPL32Null7
SUPPL33Null0
SUPPL34Null15
SUPPL35Null6
SUPPL37Null31
SUPPL39Null15
SUPPL40Null15
SUPPL41Null6
SUPPL42Null6
SUPPL43Null7

TE Codes

002PrescriptionAB

CDER Filings

PFIZER
cder:Array
(
    [0] => Array
        (
            [ApplNo] => 21130
            [companyName] => PFIZER
            [docInserts] => ["",""]
            [products] => [{"drugName":"ZYVOX","activeIngredients":"LINEZOLID","strength":"400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","dosageForm":"TABLET;ORAL","marketingStatus":"Discontinued","te":"None","rld":"Yes","rs":"No"},{"drugName":"ZYVOX","activeIngredients":"LINEZOLID","strength":"600MG","dosageForm":"TABLET;ORAL","marketingStatus":"Prescription","te":"","rld":"Yes","rs":"Yes"}]
            [labels] => [{"actionDate":"10\/26\/2021","submission":"SUPPL-43","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2021\\\/021130s043,021131s039,021132s042lbl.pdf\"}]","notes":""},{"actionDate":"09\/01\/2021","submission":"SUPPL-42","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2021\\\/021130s042,021131s038,021132s041lbl.pdf\"}]","notes":""},{"actionDate":"07\/16\/2021","submission":"SUPPL-41","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2021\\\/021130s041,021131s037,021132s040lbl.pdf\"}]","notes":""},{"actionDate":"08\/05\/2020","submission":"SUPPL-40","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/021130s039s040,021131s034s035,021132s038s039lbl.pdf\"}]","notes":""},{"actionDate":"08\/05\/2020","submission":"SUPPL-40","supplementCategories":"Labeling-Container\/Carton Labels","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/021130s039s040,021131s034s035,021132s038s039lbl.pdf\"}]","notes":""},{"actionDate":"08\/05\/2020","submission":"SUPPL-39","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/021130s039s040,021131s034s035,021132s038s039lbl.pdf\"}]","notes":""},{"actionDate":"02\/01\/2018","submission":"SUPPL-37","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2018\\\/021130s037,021131s030,021132s035lbl.pdf\"}]","notes":""},{"actionDate":"07\/13\/2017","submission":"SUPPL-34","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2017\\\/021130Origs034,021131Orig1s028,021132Orig1s033lbl.pdf\"}]","notes":""},{"actionDate":"07\/13\/2017","submission":"SUPPL-34","supplementCategories":"Labeling-Container\/Carton Labels","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2017\\\/021130Origs034,021131Orig1s028,021132Orig1s033lbl.pdf\"}]","notes":""},{"actionDate":"06\/05\/2015","submission":"SUPPL-35","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2015\\\/021130s030,021131s029,021132s034lbl.pdf\"}]","notes":"Please see"},{"actionDate":"01\/24\/2014","submission":"SUPPL-32","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2014\\\/021130s032,021131s026,021132s031lbl.pdf\"}]","notes":""},{"actionDate":"05\/03\/2013","submission":"SUPPL-24","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2013\\\/021130s023s024,021131s021s022,021132s022s023lbl.pdf\"}]","notes":""},{"actionDate":"05\/03\/2013","submission":"SUPPL-23","supplementCategories":"Labeling","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2013\\\/021130s023s024,021131s021s022,021132s022s023lbl.pdf\"}]","notes":""},{"actionDate":"02\/13\/2012","submission":"SUPPL-28","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2012\\\/021130s028lbl.pdf\"}]","notes":""},{"actionDate":"07\/16\/2010","submission":"SUPPL-22","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2010\\\/021130s022lbl.pdf\"}]","notes":""},{"actionDate":"12\/08\/2009","submission":"SUPPL-20","supplementCategories":"Labeling","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2009\\\/021130s020,021131s017,021132s018lbl.pdf\"}]","notes":""},{"actionDate":"06\/20\/2008","submission":"SUPPL-16","supplementCategories":"Labeling","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2008\\\/021130s016,021131s013,021132s014lbl.pdf\"}]","notes":""},{"actionDate":"04\/26\/2007","submission":"SUPPL-12","supplementCategories":"Labeling","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2007\\\/021130s012,021131s012,021132s012lbl.pdf\"}]","notes":""},{"actionDate":"05\/12\/2005","submission":"SUPPL-9","supplementCategories":"Efficacy-Labeling Change With Clinical Data","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2005\\\/021130s008,009,021131s009,010,021132s008,009lbl.pdf\"}]","notes":""},{"actionDate":"05\/12\/2005","submission":"SUPPL-8","supplementCategories":"Labeling","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2005\\\/021130s008,009,021131s009,010,021132s008,009lbl.pdf\"}]","notes":""},{"actionDate":"06\/23\/2004","submission":"SUPPL-6","supplementCategories":"Efficacy-New Patient Population","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2004\\\/21130se5-006,21131se5-007,21132se5-006_zyvox_lbl.pdf\"}]","notes":""},{"actionDate":"12\/19\/2002","submission":"SUPPL-3","supplementCategories":"Efficacy-New Patient Population","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2002\\\/21132se5-003,21131se5-003,21130se5-003_zyvox_lbl.pdf\"}]","notes":""},{"actionDate":"12\/19\/2002","submission":"SUPPL-2","supplementCategories":"Labeling","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2002\\\/21130slr002,21131slr002,21132slr002_zyvox_lbl.pdf\"}]","notes":""},{"actionDate":"04\/18\/2000","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2000\\\/21130lbl.pdf\"}]","notes":""}]
            [originalApprovals] => [{"actionDate":"ZYVOX","submission":"LINEZOLID","actionType":"400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","submissionClassification":"TABLET;ORAL","reviewPriority":"Discontinued","inserts":"[]","notes":">Yes"},{"actionDate":"ZYVOX","submission":"LINEZOLID","actionType":"600MG","submissionClassification":"TABLET;ORAL","reviewPriority":"Prescription","inserts":"[]","notes":">Yes"}]
            [supplements] => 
            [actionDate] => 2021-10-26
        )

)

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.